IGC Pharma, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended March 31, 2023; comparison is FY2022, ended March 31, 2022. This is an annual filing, not a calendar-year 2022 Q4 report. IGC is a clinical-stage pharmaceutical company with Life Sciences and Infrastructure segments. Its lead candidate, IGC-AD1, is being tested for agitation associated with Alzheimer’s disease; the company also sells wellness products and provides infrastructure construction and equipment rental services.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0.911 million | $0.397 million |
| Gross profit / margin | $0.442 million / approximately 49% | $0.194 million / approximately 49% |
| SG&A expense | $8.552 million | $13.292 million |
| Research and development | $3.461 million | $2.330 million |
| Operating loss | $11.571 million | $15.428 million |
| Net loss / loss per share | $11.506 million / $0.22 | $15.016 million / $0.30 |
| Cash from operating activities | $(7.047) million | $(7.462) million |
Revenue rose 129%. Life Sciences generated $798,000 (88% of revenue), including $416,000 from wellness and lifestyle products and $382,000 from white-label services. Infrastructure contributed $113,000. SG&A fell 36%, primarily because of fewer one-time expenses; R&D rose 49% as Phase 2 work and TGR-63 preclinical studies advanced. Fiscal 2022 other income included approximately $430,000 of PPP loan forgiveness, which did not recur.
Cash and cash equivalents were $3.196 million at year-end, down from $10.460 million; working capital was $4.568 million, down from $12.670 million. Investing activities used $235,000 and financing activities provided $100,000. The balance sheet showed $141,000 of long-term loans and $3,000 of short-term loans, plus operating lease liabilities of $340,000 in total. The company reported total liabilities of $2.267 million.
Material changes and developments
- IGC-AD1 Phase 2B began at two U.S. sites in December 2022; the company received a Health Canada no-objection letter in January 2023. The planned trial is designed for 146 participants, with a six-week treatment period. Management estimated 12–18 months to complete, subject to uncertainties.
- FY2023 revenue growth reflected higher sales and marketing activity, particularly increased white-label sales. The filing says two Life Sciences customers each represented over 10% of sales; Infrastructure had one customer and one subcontractor/supplier.
- Inventory declined to $2.651 million from $3.548 million. The company charged $376,000 of inventory-related expiration, handling, scrap, and spoilage costs to SG&A, versus $252,000 in FY2022.
- After year-end, on June 30, 2023, the company obtained a $12 million working-capital credit facility and sold 10 million shares for $3 million. These transactions occurred after the March 31, 2023 balance-sheet date.
Outlook, risks, and unusual items
- No specific revenue or earnings guidance is provided. Management expects continued losses and negative operating cash flow in the near term and anticipates R&D expense may increase as IGC-AD1 and TGR-63 development progresses. It plans to seek additional capital, including private placements and ATM offerings; future equity financing may dilute shareholders.
- Management stated that cash, working capital, and the subsequent financing were expected to support operations beyond twelve months after issuance of the financial statements, while cautioning that estimates depend on assumptions. The company remains unprofitable and dependent on financing.
- IGC-AD1 remains investigational and has not received marketing approval. The Phase 1 study was small; reported safety findings included no serious or life-threatening events or deaths, while some participants reported adverse events. Reported symptom improvements are early-stage findings and do not establish efficacy in the ongoing Phase 2 trial.
- Key risks include clinical-trial enrollment, safety and efficacy outcomes, FDA approval, funding access, cannabinoid regulation, customer concentration, supply delays, inventory recoverability, foreign currency exposure, and competition. COVID-related trial and supply disruptions were reported as possible continuing risks.
- The company described the remaining Apogee-related litigation as ordinary and routine and denied liability. A decision on summary judgment was expected during FY2024; the filing said the matters were not material to the consolidated financial statements.
Important facts for investors to verify
- Terms, availability, covenants, and actual drawdowns under the $12 million credit facility, and the use of the $3 million equity proceeds.
- Phase 2B enrollment, trial timing, safety updates, and results against the prespecified primary endpoint.
- Whether Life Sciences sales growth is sustained and how much revenue depends on significant customers and white-label business.
- Cash burn, working-capital needs, inventory quality and sell-through, and the amount and potential dilution of future financing.
- Progress and regulatory pathway for TGR-63, and the status and outcome of the Apogee litigation.
The financial statements received an unqualified audit opinion. The auditor reported no critical audit matters; management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2023.